Jiangsu Zhonghui Yuantong Biotechnology Co. Ltd. was founded in Taizhou, Jiangsu Province, China in 2015. The company is committed to research, development and commercialization of innovative human vaccines to prevent and treat infectious diseases, achieving international standards of excellence. Zhonghui has a manufacturing area of 50,000 square meters (phase I) that consists of the manufacturing facilities, central laboratories, an animal facility, a R&D complex building, a power center, a warehouse and other supporting facilities, all of which meet the requirements of national standards. A vaccine production license has been granted to the GMP production lines for influenza vaccine. The 2nd phase facility construction of 80 mu is underway for the commercial production of other vaccines. In Zhangjiang High Tech Park, Shanghai, Yither Biotechnology (Shanghai) Co. Ltd., a wholly-owned subsidiary Research Centre, was founded in 2020, focusing on development of novel vaccine pipelines. At present, the company has more than 500 employees in Taizhou and 100 in Shanghai, led by a core team made of experts and leaders who have many years of experience in R&D, testing and manufacturing of biological products at home and abroad. With its own patented technology, Zhonghui launched its first product, the quadrivalent influenza subunit vaccine (adult), Huierkangxin in China in May 2023. The company has also completed phase II clinical studies of the influenza subunit vaccine for children with phase III in progress. Other vaccine candidates such as 23-valent pneumococcal polysaccharide vaccineandrabies vaccine are under different stages of clinical studies. The company has invested and continues to increase the R&D investment to promote multiple pipelines using various technology platforms including conjugate vaccine, recombinant protein subunit vaccine and mRNA vaccine. Various vaccine candidates such as Pneumo conjugate vaccine and Pox mRNA vaccine candidate are under pre-clinical stage. Zhonghui has been granted 28 technical invention patents and 9 national registered trademarks. The company has won the honorary titles of "A potential Unicorn Enterprise of Jiangsu High Tech Industrial Development Zone, 2020", "A Private Enterprise of Science and Technology of Jiangsu Province" and one of the "Top ten Investment Projects for Innovation and Industrial Transformation in Taizhou". Zhonghui will carry forward the company’s motto of “Accountable, reliable, self-discipline, collaborative, and striving for a standard of excellence”. With the unremitting effort of every member of the company, Zhonghui will contribute to the protection of global public health through development and supply of high-quality vaccine products.